Erasca releases corporate presentation outlining RAS/MAPK cancer drug pipeline

• Erasca outlined a strategy centered on shutting down the RAS/MAPK pathway, led by ERAS-0015, a pan-RAS molecular glue, and ERAS-4001, a pan-KRAS inhibitor.
• Early clinical readouts for ERAS-0015 in 2L+ KRAS G12X non-small cell lung cancer showed a 63% uORR in a China study at 16-24 mg once daily (N=27), with 100% disease control.
• In a US study, ERAS-0015 posted a 58% uORR across doses in 2L+ KRAS G12X NSCLC (N=12), with a 71% uORR in post-ICI/platinum patients (N=7).
• Pharmacologically active dosing was described at 16-32 mg once daily, with 24 mg and 32 mg selected as recommended doses for expansion.
• Cash, cash equivalents, and marketable securities totaled $409 million as of March 31, 2026, with runway projected into H2 2028.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Erasca Inc. published the original content used to generate this news brief on May 19, 2026, and is solely responsible for the information contained therein.